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ABSTRACT 
 
IDENTIFICATION OF GENES INVOLVED IN HEPATOCELLULAR 
CARCINOMA; 
EVALUATION OF hCdc4 and B-Raf GENES 
 
Banu SÜRÜCÜ 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. Cengiz YAKICIER 
September 2003, 56 pages 
 
Hepatocellular carcinoma (HCC), the major type of primary liver cancer, is one of the 
most common cancers worldwide. Development and progression of HCC occur as a 
multistep process, requiring the activation of oncogenes and the inactivation of several 
tumor suppressor genes. Although, inactivation of tumor suppressor genes, including 
p53, Axin and activation of oncogene β-catenin, have been shown to be involved in 
HCC development, the molecular mechanism of hepatocarcinogenesis is still unclear. 
The identification of additional genes that are involved in hepatocarcinogenesis is, not 
only, an important task to understand this process, but also for development of novel 
strategies for prevention or therapy. 
The aim of this study was to elucidate a possible function of hCdc4 and B-Raf genes in 
HCCs.  
A gene or genes on chromosome 4q have been implicated in hepatocarcinogenesis by 
the observation of frequent deletions of this region in HCCs. More recently, hCdc4, a 
gene in this region has been proposed as a candidate tumor suppressor gene. hCdc4 is 
an F-box protein which is shown to be involved in ubiquitination of cyclin E, thus 
targeting it for destruction. Cyclin E overexpression, is reported to be a frequent event 
in different cancers including HCC suggesting a problem in its destruction. 15 HCC cell 
lines were analysed for expression and mutation of hCdc4 gene by RT-PCR and direct 
sequencing of PCR products. No abnormal transcript and mutation observed in HCC 
cell lines tested. Our findings suggest that alteration of this gene is not a frequent event 
in hepatocarcinogenesis.  
 iv 
B-Raf, which is one of the human isoforms of RAF, is activated by oncogenic Ras 
(leading to cooperative effects in cells responding to growth factor signals). B-Raf 
mutations are found in a wide range of cancers. Eventhough, mutational activation of 
Ras is not a frequent event in human hepatocarcinogenesis, few Ras mutations were 
reported in HCC cases. Thus activation of oncogenic MAP kinase pathway by another 
component of this pathway such as BRAF is worth to analyze. HCC cell lines and 
tumours were searched for B-Raf mutations. Activating BRAF missense mutations were 
identified in 2/72 HCCs (3%). Our results suggest that B-Raf may be occasionally 
involved in hepatocarcinogenesis. Thus MAP kinase pathway might be involved in 
hepatocarcinogenesis but neither B-Raf nor Ras are the major players of this pathway in 
this event. For this reason, other members of this pathway should be evaluated for 
mutations in HCC. 
 
Keywords: HCC, hCdc4, B-Raf, oncogene, tumor suppressor gene, mutation. 
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ÖZET 
 
HEPATOSELÜLER KARSİNOMDA ROL ALAN GENLERİN 
TANIMLANMASI: hCdc4 VE B-Raf GENLERİNİN DEĞERLENDİRİLMESİ 
 
Banu SÜRÜCÜ 
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi: Yard. Doç. Dr. Cengiz YAKICIER 
Eylül 2003, 56 sayfa 
Karaciğer kanserinin başlıca türü olan hepatoselüler karsinom (HCC) dünya çapında 
yaygın kanserlerden biridir. HCC’nin oluşması ve gelişimi çok basamaklı bir süreç olup 
onkogenlerin aktivasyonunu ve/veya tümör baskılayıcı genlerin inaktivasyonunu 
gerektirir. Her ne kadar p53, aksin gibi tümör baskılayıcı genlerin inhibisyonu ve β-
katenin gibi onkogenlerin aktivasyonu gösterildiyse de hepatoselüler karsinomun 
moleküler mekanizması belirgin değildir. Bu nedenle, hepatokarsinogenezde rolü olan 
genlerin tanımlanması sadece bu sürecin anlaşılmasında değil aynı zamanda koruma 
veya tedavi için yeni stratejiler geliştirilmesinde de önemli bir basamaktır. 
Bu çalışmanın amacı hCdc4 ve B-Raf genlerinin HCC’deki olası rollerini 
değerlendirmektir. 
Kromozom 4q üzerinde sık görülen delesyonlar nedeniyle bu bölgede bulunan gen ya 
da genlerin HCC’de rol alabileceği düşünülmektedir. Yakın zamanda bu bölgede 
bulunan bir gen olan hCdc4 klonlanmış ve olası bir tümör baskılayıcı gen olarak 
gösterilmiştir. hCdc4 bir F-box proteini olup siklin E’nin ubikütinlenmesinde 
dolayısıyla da yıkımında rol aldığı gösterilmiştir.Yıkımındaki bir bozukluk dolayısıyla 
olabilecek siklin E ekspresyon seviyesindeki artış, HCC’nin de içinde bulunduğu çeşitli 
kanserlerde sık görülen bir olaydır. 15 HCC hücre hattında hCdc4 geninin ekspresyon 
ve mutasyon çalışmaları RT-PCR ve bunu takiben PCR ürünlerinin direkt DNA dizi 
analizi yöntemleri kullanılarak incelenmiştir. Test edilen HCC hücre hatlarında 
mutasyon veya anormal transkript  gözlemlenmemiştir. Bu bulgular hCdc4 genindeki 
değişimlerin hepatokarsinogenezde sık rastlanan bir olay olmadığına işaret etmektedir. 
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RAF proteininin insan isoformlarından biri olan B-RAF onkogenik RAS tarafından 
aktive edilerek hücrelerin büyüme faktörlerine yanıt vermesinde işlev görür.. B-Raf 
mutasyonları birçok kanser türünde gösterilmiştir. RAS mutasyonları insan 
hepatokarsinogenezinde sık görülen bir olay olmasa da HCC örneklerinde az sayıda 
rapor edilmiştir. Bu nedenle onkogenik MAP kinaz yolağının aktivasyonunun B-RAF 
gibi başka bir bileşeni tarafından aktive edilmesi olasıdır. B-Raf mutasyonları  HCC 
hücre hatları ve tümörlerinde araştırılmıştır ve aktive edici B-Raf mutasyonları 
HCC’lerin %3’ünde (2/72) tanımlanmıştır. Bu bulgular B-Raf geninin, dolayısıyla bu 
yolağın hepatokarsinogenezde rol alabileceğini ancak ne B-Raf ne de ras geninin 
hepatokarsinogenezde rol oynayan başlıca genler olmadığını göstermektedir. Bu 
nedenle MAP kinaz yolağının diğer üyelerinin HCC’deki mutasyonları 
değerlendirilmelidir. 
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1. INTRODUCTION
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1.1. Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is a malignant tumour derived from hepatocytes. HCC 
is fifth most common malignant disease worldwide with an estimated 564,000 new 
cases diagnosed annually and fourth in cancer mortality after lung, stomach and colon 
cancers (Parkin et al., 2001a; Parkin, 2001b). HCC is the predominant cause of cancer 
mortality in Southern and Sub-Saharan Africa, Taiwan and China. Its incidence is 
variable and higher in these regions. This geographic pattern overlaps with the 
distribution of risk factors and probably also reflects genetic characteristics inherited or 
acquired through oncogenic agents. (Figure 1.1, Table 1.1) 
 
 
 
Figure 1.1: Worldwide incidences of HCC. Worldwide incidences of HCC with pie diagrams of 
p53mutation patterns for various countries and continents according to the IARC p53 mutation database. 
(www.iarc.fr/p53/index.html). A high frequency of G:C to T:A mutations is found in high incidence areas 
of both endemic HBV infection and dietary AFB1 exposure. (Staib et al., 2003) 
 
However, several studies have demonstrated a significant increase in the incidence of 
HCC in many countries in low incidence areas in the last few decades including areas of 
previously low incidence such as Northern Europe, Northern America and Japan. This 
increase reflects the strong impact of environmental factors on the pathogenesis of the 
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tumor. In areas where Hepatitis C Virus (HCV) infection is frequent, particularly in 
Japan HCC cases are associated with chronic HCV infection. 80% of HCC cases are 
associated with chronic HCV infection. In contrast, the prevalence of HBV-associated 
HCC has been rather stable in most parts of the world; therefore the increase of HCC is 
linked to increased chronic HCV infection. (Okuda K. 2000) (Figure 1.2) 
 
Established and principally suspected risk factors for HCC: 
-Associated with chronic liver disease and /or cirrhosis: 
Hepatitis B virus 
Hepatitis C virus 
Alcohol 
Cryptogenic cirrhosis 
Primary biliary cirrhosis 
Autoimmune chronic active hepatitis 
Hemochromatosis 
Wilson’s disease 
Glycogen storage disease 
Other causes of cirrhosis 
  
-Without necroinflammatory liver disease: 
Aflatoxin B1 (p53 codon 249 3rd position G? T) 
Contraceptive and anabolic steroids 
Vinyl chloride 
Azathioprine 
Polychlorinated biphenyls 
Arsenic 
Other chemical carcinogens 
 
Table 1.1: Risk factors for HCC. (Modified from Ozturk M., 1999) 
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Figure 1.2: Etiology of HCC. The percentage of worldwide HCC associated with HBV, HCV or other 
causes is shown. Data are from GLOBOCAN 2001 and Parkin et al., 2001 
 
 
1.1.1. HCC Biology 
Under normal conditions, adult hepatocytes are non-dividing cells. Only a minor 
fraction undergoes cell division due to aging or apoptosis. Any type of injury (such as 
chronic HBV or HCV infection) provokes proliferation of hepatocytes in order to 
replace defective hepatocytes. (Regeneration). Chronic liver regeneration may itself be 
a source of spontaneous gene mutations as well as other hepatotoxic factors and lead to 
genomic instability and progression of liver malignancy. (Cetin-Atalay and Ozturk, 
2002) 
 
 
Figure 1.3: Multistage Hepatocarcinogenesis. (HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; 
AFB1: Aflatoxin B1) (Thorgeirsson and Grisham, 2002) 
 
Hepatocarcinogenesis is a multi-step process, which involves genetic alterations that 
drive the progressive transformation of normal hepatocytes into highly malignant 
 5 
derivatives. (Figure 1.3) Cancer cells have defects in regulatory circuits that govern 
normal cell proliferation and homeostasis. Six essential alterations in cell physiology 
that collectively dictate malignant growth are (Hanahan and Weinberg, 2000): 
1) Self-sufficiency in growth signals 
Instead of being dependent on exogenous growth factors to stimulate growth and 
cell proliferation, tumour cells can grow and divide without these exogenous 
signals. This is often caused by mutations in genes that encode components of the 
signalling pathways that normally regulate these processes.  Such mutations lead to 
constitutively active growth signalling (eg. mutations in Ras). 
2) Insensitivity to growth inhibitory (anti-growth) signals 
The growth and proliferation of cells is controlled by the balance of growth 
promoting signals and growth inhibitory (or anti-growth) signals. The loss of growth 
inhibitory signals or the loss of the ability to respond to these signals is typical of 
tumour cells (eg. mutations in Smad4 gene in TGF-beta pathway). 
3) Evasion of apoptosis 
A critical component of normal tissue homeostasis is apoptosis (programmed cell 
death). This allows the control of cell number and is also a mechanism for the 
removal of unwanted cells, for example those with significant damage like genetic 
damage. Tumour cells have often developed mutations in key genes whose products 
are involved in apoptosis, causing the blockage of cell death (eg. p53 mutations in 
HCCs). Another mechanism that can lead to the same functional effect is the over-
expression of some genes whose normal function is to encode proteins that suppress 
cell death (eg. bcl-2). 
4) Limitless replicative potential 
Normal cells have a restricted replicative potential as a consequence of a number of 
mechanisms. One important mechanism relates to the progressive shortening of 
chromosome ends (telomeres) at every cell division. Tumour cells have an 
unrestricted replicative potential, in part, because they overcome the chromosome 
shortening by the production of an enzyme called telomerase. 
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5) Sustained angiogenesis 
While tumours grow by the above mechanisms at some point they will stop growing 
because they will outgrow their blood supply, which provides the necessary 
nutrients and oxygen. Tumours overcome this problem by the production of various 
factors that stimulate the formation of new blood vessels (eg. VEGF). 
6) Tissue invasion and metastasis 
Normal cells resides where they belong and tissue boundaries are normally 
maintained. Tumours are characterised by invasion into nearby tissues and 
structures (ie. normal boundaries are not maintained) and may spread to distant sites 
(metastasis). These properties are the main reason why tumours are such a 
significant clinical problem. 
As mentioned above these characteristics may be gained by accumulation of mutations 
in the genes that play crucial roles in cellular homeostasis. 
 
1.1.2. HCC Genetics 
HCC may be produced by selection of both genomic and epigenetic alterations that 
compromise more than one regulatory pathway (Thorgeirsson and Grisham, 2002). It 
has been shown that HCCs display many genetic alterations including polyploidy, 
allelic imbalance, amplifications, translocations, inverted duplications, deletions, de 
novo methylation and loss of heterozygosity (LOH). (Cetin-Atalay and Ozturk, 2002; 
Buendia, 2000; Puig et al., 2001) 
 
There are more than 20 genes involved in at least 4 carcinogenesis pathways that are 
shown to be altered in HCC. (Buendia et al., 2000). Most of the genes mutated in HCC 
are tumour suppressor genes and frequent allelic losses (LOH) leading to biallelic 
inactivation have been described. (Puig et al., 2001) (Table 1.2) 
 
One of them is p53 TSG (tumour suppressor gene) which is frequently mutated in 
human cancers and its mutations is found in about 30% of HCCs worldwide. The 
frequency of all p53 mutations varies between 20% (USA) and 67% (Senegal). A 
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specific mutation in codon 249 of the p53 gene was found in about 50% of HCC in 
populations exposed to aflatoxin B1 (Mozambique, Senegal, China) and the presence of 
this hot spot mutation in patients with HCC from Europe, the USA, Japan and Australia 
is extremely low. (Bressac et al., 1991; Hsu et al., 1991; Oda et al., 1992; Buetow et al., 
1992) Activation of the Wnt/wingless pathway can be caused by a stabilizing mutation 
of β-catenin gene or by an inactivating mutation of the Axin1 gene (Miyoshi et al., 
1998; de La Coste et al., 1998; Legoix et al., 1999; Satoh et al., 2000). Somatic 
mutations of both β-catenin and Axin1 genes have been observed in 20-25% and 5-10% 
of HCC cases respectively. Less frequently observed in HCC are the inactivating RB1 
and p16 mutations. In contrary, inactivation of p16 by homozygous mutation and 
methylation are shown to be frequent in HCCs. Overexpression of cyclin D1 and 
increased RB1 degradation by overexpression of gankyrin lead to the alteration of RB1 
pathway, this plays a significant role in HCC development. (Zhang et al., 1994; 
Higashitsuji et al., 2000). Finally, rare IGF2R, SMAD2, and SMAD4 inactivating gene 
mutations can alter the transforming growth factor β pathway (De Souza et al., 1995; 
Kawate et al., 1999; Yakicier et al., 1999). 
Some genes mutated in Hepatocellular Carcinoma includes: 
 
Frequently mutated genes  
P53  (10-50 %) 
β-catenin  (13-89 %) 
   
Less frequently mutated genes: 
M6P/ IGF2R  (0-33 %) 
SMAD2  (0-2 %) 
SMAD4  (0-6 %) 
Rb1  (~ 15%) 
Axin  (~ 5%) 
Cmet  (0-30 %) 
BRCA2  (~5 %) 
PTEN/MMAC1  (0-5 %) 
 
Table1.2: Some genes involved in HCC (modified from Ozturk M., 1999) 
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LOH is the most common genetic aberration observed in HCCs. Some chromosomes 
display frequent losses (more than 20%); which implies that either the development or 
persistence of these changes is not random. It has been suggested that each frequently 
effected region may contain one or more genes whose loss or altered function 
contributes to the development and/or progression of HCC. (Figure 1.4) 
 
 
Figure 1.4: Frequency of LOH (Loss of Heterozygosity) vs. Chromosomal arms lost in HCC 
 
Although implication of several genes (Table 1.2) have been shown in HCCs, as 
indicated in figure 1.4 there are still chromosomes that contain unidentified TSGs, In 
addition, for several chromosomes number of observed mutations or methylations do 
not correspond to that of LOH. For instance the LOH of several markers on 17p13.3 
occurred at a higher frequency than that of p53 locus, which is located on 17p13.1. 
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These findings suggest the existence of one or more genes involved in HCC on 17p13 
in addition to p53 gene. (Zhao et al., 2001) 
 
In addition to LOH studies CGH (Comparative Genomic Hybridization) and microarray 
studies also reveal that there are still more locus involved in HCCs. In contrast to allelic 
losses and TSGs, some regions (1p, 6p, 8q, 17q) or genes are consistently amplified or 
over expressed. (Figure 1.5) 
 
Previously, the amplification and/or overexpression of cyclin D1 and c-Myc have been 
shown in advanced human HCCs. In addition to the human HCC data, in woodchucks, 
about 50% of hepatocellular carcinomas arising in animals infected chronically with 
WHV (woodchuck hepatitis virus). Viral DNA sequences were integrated in or adjacent 
to c-myc or N-myc genes. On the other hand in a transgenic mice model, overexpression 
of cyclin D1 is sufficient to initiate hepatocellular carcinogenesis. (Nishida et al., 1994; 
Deane et al., 2001) 
 
All these studies with CGH and microarray data suggest that oncogenic gene activation 
in addition to TSGs inactivation is important in hepatocarcinogenesis. Thus the β-
catenin is not the unique oncogene that is involved in human HCC development. 
 
Altogether, epidemiological, genetic, and biological data suggest there are still genes 
that participate hepatocarcinogenesis to be identified. 
 
The aim of our study is to identify genes that are involved in HCC development. To 
achieve this aim we searched the literature for possible candidates that may have role in 
hepatocarcinogenesis.
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Figure 1.5: Summary of gains and losses detected by CGH. Vertical lines on the left of each chromosome ideogram represent loss of chromosomes, whereas 
vertical lines on the right correspond to chromosomal gains. Available in http://www.progenetix.de/12048165_P/ideogram.html 
(Chang et al., 2002)
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1.2. hCdc4 /Archipelago  / Fbwx7 / SEL10: 
 
Cyclin dependent kinase 2 (cdk2) activated by Cyclin E is involved in the initiation of 
DNA replication and other S phase events. In parallel with this role, cyclin E protein is 
accumulated at the G1? S phase transition and decreases during early S phase. This 
increase and decrease is a result of periodic transcription and ubiquitin-mediated 
proteolysis in control of SCFhcdc4. SCF ubiquitin ligases are composed of a core complex 
linked to a variable component, which is called F-box protein that provides substrate 
specificity. hCdc4 (also designated as Fbwx7 or Ago) is identified as the F-box protein 
that is involved in the ubiquitin mediated degradation of Cyclin E. Defects in proteolysis 
of Cyclin E can lead to accelerated entry to S phase leading to genetic instability that may 
result in tumourigenesis. Indeed, many kinds of HCC tumours show elevated levels of 
cyclin E protein but not mRNA. (Strohmaier et al. 2001, Moberg et al. 2001, Koepp et 
al., 2001). It has been found that hCdc4 is mutated in human endometrial tumors (16%), 
ovarian and breast carcinoma cell lines. 
 
Moberg et al. used Drosophila as model organism to identify the loci that are involved in 
cellular proliferation. By screening the Drosophila mutants, they identified over 23 loci 
one of which it was termed as archipelago (ago). Within ago mutant clones, the 
ommatidial clusters of the retina contained extra cells that seemed to be resulted from 
extra cell divisions. Therefore, ago-mutant cells were examined for increased level of 
positive cell cycle regulators and it was found that Cyclin E protein, but no other cyclins 
or cyclin E mRNA level, is increased. Archipelago protein contained seven WD repeats 
and an F-box, which is a common signature in SCF complexes that have role in selection 
of proteins for ubiquitination. Moberg et al. showed that Archipelago could bind to 
Cyclin E, which may indicate the ability of Archipelago to target Cyclin E for 
ubiquitination. 
 
Two other groups using yeast as model organism started from the assumption that SCF 
complex may be involved in turnover of Cyclin E. It was found that levels of Cyclin E 
are stabilized in SCF mutant strains of yeast compared to wild type. And a protein that 
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was termed as Fbwx7 (Koepp et al., 2001) or Cdc4 (Strohmaier et al., 2001) was 
identified. Overexpression of Fbwx7 was shown to decrease the levels of Cyclin E while 
its inhibition resulted in Cyclin E accumulation (Koepp et al., 2001). Human homologue 
of yeast Cdc4 (hCdc4) was identified and it was confirmed that this protein is a part of 
SCF complex and it can ubiquitinate Cyclin E in a phosphorylation dependent manner 
(Strohmaier et al., 2001). Later, it was shown that this protein is mutated in breast and 
ovarian carcinoma cell lines. (Schwab and Tyers, 2001; Mitchell A., 2001) 
 
The levels of Cyclin E protein in HCC cell lines that we used in our study are shown in 
Table 1.3: 
 
 Cell lines 
Cyclin E protein 
level 
1 Huh 7 * 
2 BTR * * 
3 Focus * * * * 
4 MV * * 
5 Hep 40 * * * * 
6 Hep 3B * * * * 
7 Hep G2 * * * * * 
8 PLC * * * 
9 SK Hep1 * * * 
10 Snu 475 * * * * * 
11 Snu 449 * * * * * 
12 Snu 423 * * * * * 
13 Snu 398 * * * * 
14 Snu 387 * 
15 Snu 182 * * 
*            very weak band 
* *         weak band 
* * *       band 
* * * *     strong band 
* * * * *  very strong band 
 
Table 1.3: Cyclin E protein levels in HCC cell lines.
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1.3. B-Raf 
 
Raf genes were first identified as oncogenes in retroviruses that were causative agents of 
tumours in mice and chickens (Rapp et al., 1983; Jansen et al., 1984; Sutrave et al., 
1984). Homologues of these genes are found in higher eukaryotes including C. elegans, 
D. melanogaster, X. laevis, chicken, mouse, rat and humans. In mammals, three related 
genes have been identified, namely A-RAF, B-RAF and RAF1 (also known as C-RAF or 
C-RAF1). The RAF-1 protein is expressed at high levels in most cell types and tissues. 
By contrast B-RAF has a highly restricted pattern of expression, mainly expressed in 
neuronal tissue, testis and spleen (Storm et al., 1990; Luckett et al., 2000; Barnier et al., 
1995). However, studies to identify activated versions of raf genes in human cancers 
showed no consistent correlation. Instead, the motivation for studying Raf proteins with 
regard to human cancer was the discovery that they are key effectors of Ras proteins 
(Sutrave et al., 1984), oncogenic mutations of which are detected in a large percentage of 
human cancers (Bos et al., 1984). Raf proteins play a major role in the conserved 
Ras/Raf/MEK/ERK pathway, by acting to relay signals from activated Ras proteins via 
MAPK/ERK kinase 1/2 (MEK1/2) to the p42/p44 MAP kinases or ERK 1/2, the key 
effectors of this pathway (Marshall et al., 1994; Marais et al., 1996). Raf proteins are 
activated in a Ras dependent manner. Once activated, they are able to phosphorylate and 
activate MEK1/2, which in turn phosphorylates and activates ERK1/2. ERKs have many 
substrates located in different places in the cell including transcription factors, ribosomal 
proteins, enzymes and cytoskeletal proteins. B-RAF activity in cancer samples has not 
been studied in detail so far. However, a recent report has now demonstrated the presence 
of activating mutations of the B-Raf gene in 70% of malignant melanomas and 15% of 
human colon cancers (Davies et al., 2002). While the B-Raf mutations themselves may 
not be the actual case of cancers, the high correlation in malignant melanomas suggests 
that the acquisition of B-Raf mutations are a likely prerequisite for development of these 
tumours. 
 
Studies on mice with targeted genetic mutations of the raf genes have shown that Raf-1 is 
dispensable for MEK/ERK activation and that B-RAF appears to be the key MEK/ERK 
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activator in most tissues and cell types (Wojnowski et al., 2000; Huser et al., 2001; 
Mikula et al., 2001). In addition, studies on the mechanism of regulation of B-RAF 
activation have shown that key phosphorylation events take place in B-RAF result to 
have a higher activity toward MEK than Raf-1 (Mason et al., 1999; Zhang et al., 2000). 
 
It seems that B-RAF isotype has different properties that make it stand out from its 
counterparts, RAF-1 and A-RAF. These properties can explain why this protein is 
involved in tumour development rather than the other two RAFs. 
 
1.3.1. B-Raf mutations in human cancer: 
Missense mutations of the B-Raf gene in approximately 70% of human malignant 
melanomas and 15% of colorectal cancers were detected by sequencing of 923 cancer 
samples by Davies et al. (Davies et al., 2002). Mutations were also detected at a low 
frequency in gliomas, lung cancers, sarcomas, ovarian carcinomas, breast cancers. 89 % 
of the B-Raf mutations result in amino acid changes within the activation segment, with 
the V599E (T?A change at nucleotide 1796) mutation. 
 
Eleven percent of the mutations are found in the glycine residues of the G loop 
GXGXXG motif in the ATP-binding domain of the kinase domain affecting G463, G465 
and G468 (Mercer and Pritchard, 2003). 
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Figure 1.6. MAPK pathway, Karp 2002 
  
 
2. MATERIALS 
AND METHODS 
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2.1 MATERIALS 
2.1.1 Chemicals and Enzymes 
All enzymes or reagents were purchased from the sources below: 
Material      Manufacturer 
Taq polymerase     MBI Fermentas 
dNTPs       MBI Fermentas 
Gene ruler DNA ladder mix    MBI Fermentas 
Mass Ruler DNA ladder mix    MBI Fermentas 
QIAquick Nucleotide Removal Kit   Qiagen 
QIAEX II Gel Extraction Kit    Qiagen 
Revert Aid First Strand cDNA Synthesis Kit  MBI Fermentas 
QIAamp RNA Blood Mini Kit   Qiagen 
NucleoSpin C + T    
 
2.1.2 Equipment and Manufacturers: 
Equipment:      Manufacturer 
Micropipettes 
P10       Gilson 
P20       Eppendorf 
P200       Eppendorf 
P1000       Eppendorf 
GeneAmp PCR System 96000 and 24000  Perkin Elmer 
Gel Tanks 
Horizontal Minicell     E-C Apparatus 
Horizontal Midicell     E-C Apparatus 
Power Supply PAC120    BioRad 
UV Transilluminator     BioRad Gel Doc 2000 
ABI Prism 377 Automated DNA Sequencer  Perkin Elmer 
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2.1.3 Plastic Disposables 
The list of plastic disposables used and their manufacturers are listed below: 
Disposables      Manufacturer 
Microcentrifuge Tubes    Costar 
0.2 ml 
1.5 ml 
2.0 ml 
Test Tubes      Costar 
15 ml 
50 ml 
Micropipette Tips     Costar 
Micropipette Filter Tips    Greiner 
 
2.1.4 Solutions 
Solutions for Agarose Gel Electrophoresis 
EDTA       0.5 M (stock solution), pH 8.0 
1X TBE      45 mM Tris-Borate, 1mM EDTA 
1X Loading Buffer   0.25 % bromophenol blue, 
0.25 % xylene cyanol,  
50 % glycerol, 
1 mM EDTA 
EtBr       10 mg/ml in water (stock solution) 
        
 19 
2.2. METHODS 
2.2.1 Cell lines 
15 HCC cell lines used in the experiments were kindly provided by Mehmet Ozturk’s 
Group.  
 
 Cell Lines Mutational Status 
1) Huh 7 P53 mutation  
2) Hep3B-TR  
3) Focus P53 mutation  
4) Mahlavu P53 mutation  
5) Hep 40  
6) Hep 3B P53 mutation  
7) Hep G2 Β-catenin, Ras mutation  
8) PLC/PRF/5 P53 mutation  
9) SK-Hep1 B-Raf mutation  
10) SNU 475 P53 mutation  
11) SNU449 P53 mutation  
12) SNU423  
13) SNU398 Β-catenin, p53 mutation  
14) SNU387 P53 mutation  
15) SNU182 P53 mutation  
 
Table 2.1 :Cell lines used and their mutational status. 
 
2.2.2 Primers 
All oligonucleotides were designed by Primer3 program (PCR primer selection tool at 
Whitehead Institute for Biomedical Research, http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi) and were obtained from IONTEK (Istanbul, Turkey). 
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hCdc4   PRIMER SEQUENCE   Length 
hCdc4-1F   5'-TCTGATAGTCTAGCCAAGGTCCA-3'   23bs 
hCdc4-1R   5'-TCCATCTCCTCCTCCTCCTCA-3'   21bs  
         
hCdc4-2F   5'-AGGAAGATGAAGAACATGCTGGT-3'   23bs 
hCdc4-2R   5'-TGTAGGTGGCTGGACAGATG-3'   20bs 
         
hCdc4-3F   5'-TGTTCAGCAACACCAACAACT-3'   21bs 
hCdc4-3R   5'-TGGTTCATCAATCCCCTCTT-3'   20bs 
         
hCdc4-4F   5'-TCAGACATGTCGCTACTGGAGAA-3'   23bs 
hCdc4-4R   5'-CCAGTCTCTGCATTCCACACT-3'   21bs 
         
hCdc4-5F   5'-TGGATCTACAGATCGGACACT-3'   21bs 
hCdc4-5R   5'-CTGTCTCCACATCCCAAACA-3'   20bs 
         
hCdc4-6F   5'-TGATGGTATCCATGTGGTGAGT-3'   22bs 
hCdc4-6R   5'-CCCGTTTTCAAGTCCCATAG-3'   20bs 
         
hCdc4-7F   5'-ACCAGCTCAGATGATGGAACT-3'   21bs 
hCdc4-7R   5'-AAGGGCAGGGAGTATATCGT-3'   20bs 
 
B-Raf   Primer Sequence   Length 
BrafG-F   5'-AACACATTTCAAGCCCCAAA-3'   20bs 
BrafG-R   5'-GCATCTCAGGGCCAAAAAT-3'   19bs 
         
BAGN-F   5'-AGGTGATTTTGGTCTAGCTACAGT-3'   24bs 
BAGM-F   5'-AGGTGATTTTGGTCTAGCTACAGA-3'   24bs 
BAG-R   5'-TGTGGATCACACCTGCCTTA-3'   20bs 
         
Bex11-F   5'-CTTTTGGAGGAGTCCTGAAACT-3'   22bs 
Bex11-R   5'-ATCCCTCTCAGGCATAAGGT-3'   20bs 
 
Table 2.2 : Sequences of all primers used. 
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2.2.2.1 Primers for hCdc4: 
For hCdc4 gene 7 sets of overlapping primers were designed for PCR using cDNA as 
template. 1F-3R and 4F-7R primer pairs were used for PCR. 15 HCC cell lines were 
sequenced using primers below (Figure 2.1). 
 
      1F           2F            3F             4F           5F           6F         7F    
 
 
                                     1R             2R            3R           4R          5R          6R           7R 
 
Figure 2.1: Positions of hCdc4 specific primers 
 
2.2.2.2 Primers for B-Raf 
BrafG-F and BrafG-R primers were used for amplification and sequencing of exon 15 of 
the B-Raf gene. 
 
Bex11-F and Bex11-R primers were used for amplification and sequencing of exon 11 of 
B-Raf gene. 
 
For the ARMS test BAG-M and BAG-R genomic primers were used for the mutated 
allele of the B-Raf gene and BAG-N and BAG-R primers were used for the normal allele. 
 
2.2.3 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) is a rapid procedure for in vitro enzymatic 
amplification of specific desired sequences of DNA. (Mullis and Faloona et al., 1987) 
There are three distinct events during a PCR cycle: 
1) Denaturation of the template: DNA denaturation occurs when the reaction is 
heated to 92-96 ºC. 
2) Primer annealing: After denaturation the oligonucleotide primers hybridize to 
their complementary single stranded target sequences. The temperature of this 
hCdc4
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step varies depending on the homology of the primers for the target sequence as 
well as the base composition of the oligonucleotides. 
3) DNA synthesis by the thermostable Polymerase: The last step is the extension of 
the oligonucleotide primer by the Polymerase. This step of the reaction is carried 
out at 72 ºC. The larger the template, the longer is the time required for a proper 
time for the extension. Also, the time for a proper extension time may be 
increased if the GC content of the template is high. 
 
2.2.3.1 PCR conditions 
PCR conditions  hCdc4 (4F-7R 1264bp) (1F-3R 1047bp) 
First denaturation  94 ˚C     5' 
Denaturation  94 ˚C     30'' 
Annealing  58 ˚C     30'' 
Extension  72 ˚C     1' 35'' 
Last Extension  72 ˚C     5' 
Total Cycles  35 cycles 
Table 2.3: PCR conditions for hCdc4. 
 
PCR conditions B-Raf exon 15 (399bp) B-Raf ARMS (532bp) B-Raf exon 11 (357bp) 
First denaturation  94 ˚C     5' 94 ˚C     4'  94 ˚C     5' 
Denaturation  94 ˚C     30'' 94 ˚C     30''  94 ˚C     30'' 
Annealing  60 ˚C     30'' 68.5 ˚C   30''     58 ˚C     30'' 
Extension  72 ˚C     30'' 72 ˚C     40''  72 ˚C     30'' 
Last Extension  72 ˚C     5' 72 ˚C     5'  72 ˚C     5' 
Total Cycles  35 cycles 35 cycles  35 cycles 
Table 2.4: PCR conditions for hCdc4 and B-Raf. 
 
2.2.3.2 PCR mix 
PCR mix:    (50µL final volume) 
1X PCR buffer (MBI Fermentas) 
MgCl2 2 mM (MBI Fermentas) 
dNTP 0.2 mM (MBI Fermentas) 
20 pmol of each primer 
2 units Taq Polymerase (MBI Fermentas) 
1-2 ng of genomic DNA or 1 µL cDNA 
Table 2.5: PCR Mix 
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2.2.4 ARMS (Amplification Refractory Mutation System) 
ARMS test was performed in order to detect T1796A transversion resulting in V599E 
aminoacid missense mutation in exon 15 of the B-Raf gene. ARMS is also known as 
allele-specific PCR (ASPCR) or amplification of specific alleles (PASA). It was first 
described by Newton et al, 1989. ARMS may be used to detect point mutations and small 
deletions/insertions. ARMS can generally detect a single copy of the mutant allele in 40 
copies of normal allele. This system also leads to fast, reproducible and inexpensive 
results.  
 
The ARMS primers were designed so that the nucleotide distinguishing between the 
different alleles was at the 3’ terminal base of the primers (when it is specific to the 
template it will amplify and when it differs it will not). ARMS PCR consisted of two 
complementary reactions (two tubes) and utilizing 3 primers. One primer is constant and 
complementary to the template in both reactions (BAG-R), the other primers (BAGM-F 
and BAGN-F) differed at their 3’ terminal residues and are specific to either wild type 
DNA sequence (BAGN-F) or the mutated sequence at a given base. Only one of these 
allele specific primers was used per tube. If the sample is homozygous wild type 
amplification only occurred in one of the tubes, if the sample is heterozygous 
amplification was seen in both of the tubes. The cell lines and HCC tumour samples that 
are found to be (+) for the mutation were confirmed by sequencing. The tumour samples 
were kindly provided from Mehmet Ozturk’s group. SK-Hep1 cell line that was found to 
have the mutation (Davies et al., 2002) was used as (+) control. 
 
2.2.4.1 ARMS primers for normal allele 
 
AAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTT 
      >>>>>>>>>>>>>>>>>>>>>>>> 
  BAGN-F                               
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
 
CTGTGTACCCTGTTGAAAAAAAAAACAGGTATGCAATTTAAGGCAGGTGTGATCCACAGC 
                                      <<<<<<<<<<<<<<<<<<<<   
       BAG-R 
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2.2.4.2 ARMS primers for the mutated allele 
AAAAATAGGTGATTTTGGTCTAGCTACAGaGAAATCTCGATGGAGTGGGTCCCATCAGTT 
      >>>>>>>>>>>>>>>>>>>>>>>>   
  BAGM-F                               
nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
 
CTGTGTACCCTGTTGAAAAAAAAAACAGGTATGCAATTTAAGGCAGGTGTGATCCACAGC 
                                      <<<<<<<<<<<<<<<<<<<< 
         BAG-R 
                            
 
2.2.5 DNA Isolation from cell pellets 
 DNA isolation from cell lines was performed using NucleoSpin C + T kit (Macherey-
Nagel) according to manufacturer’s manual as follows: 
~ 25 mg of pellet was placed in 1.5 ml centrifuge tube and 180 µl of buffer T1 was 
added. 25 µl of proteinase K solution was added and mixed then incubated at 56ºC in 
shaking water-bath until complete lysis occurs. 200 µl buffer B3 was added to the 
sample, mixed and incubated at 70 ºC for 10 minutes. 210 µl ethanol was added and 
vortexed immediately. Then, the sample was applied to Nucleospin cup that was 
placed in a 2 ml collection tube and centrifuged for 1 minute at 6000 rpm. The filtrate 
was discarded the spin cup was washed with 500 µl buffer B5 by centrifugation for 2 
minutes at 6000 rpm. and flowthrough was discarded. The washing steps were 
repeated twice. Then the Nucleospin cup placed in the empty collection tube was 
centrifuged for 2 minutes at 6000 rpm in order to remove buffer B5, which contains 
ethanol, completely. The Nucleospin cup was placed in a clean 1.5 ml centrifuge tube 
and DNA was eluted with 100 µl preheated  (70ºC) elution buffer BE. 
 
2.2.6 RNA Isolation from cell pellets 
RNA isolation from cell lines was performed using QIAamp RNA Blood Mini Kit 
(Qiagen, catalogue # 52304) according to manufacturer’s manual as follows. 
The cell pellet was loosened by flicking the tube and 600 µl buffer RLT (Lysis buffer) 
was added and pipetted to mix until no cell clumps were visible. The lysate was put 
into the Qiashredder spin column that was placed in a 2ml collection tube and 
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centrifuged for 2 minutes at 13000 rpm to homogenize. The column was discarded 
and 600 µl 70 % ethanol was added to the homogenized lysate then mixed well by 
pipetting. The sample was pipetted into a QiaAmp spin column placed in a 2ml 
collection tube and centrifuged for 15 seconds at 10000 rpm. The spin column was 
transferred into a new collection tube and 700 µl Buffer RW was added into the spin 
column then centrifuged for 15 seconds at 10000 rpm to wash. Flowthrough was 
discarded and the column was placed into a new collection tube. 500 µl Buffer RPE 
was added into the column and centrifuged for 15 seconds at 10000 rpm to wash. 500 
µl Buffer RPE was added into the column and centrifuged for 3 minutes at 13000 
rpm. The flowthrough was discarded and the column is placed into new collection 
tube then centrifuged for 1 minute at 13000 rpm to eliminate any chance of possible 
buffer RPE carryover. To elute, the spin column was placed into a 1.5 ml collection 
tube and 50 µl of RNase-free water was added directly onto the membrane in the 
column then centrifuged for 1 minute at 10000 rpm. 
 
2.2.7 Determination of RNA concentration by Spectrophotometry 
2 µl of each sample was diluted in 1:500 ratio with sterile ddH2O. Then OD measurement 
was done at 260 and 280 nm with the spectrophotometer (Beckman). 
Concentration of RNA was calculated according to the formula: 
[RNA]= OD260 x dilution factor (500) x 40 
OD260/ OD280 ratios were calculated in order to check whether there was any protein or 
DNA contamination in the RNA samples. The expected ratio was between 1.6-2.0. 
 
2.2.8 cDNA synthesis 
cDNA synthesis was performed using RevertAid First Strand cDNA synthesis Kit (MBI 
Fermentas, #K1622) according to manufacturer’s manual as follows. 
5µg of RNA samples were mixed with 1µl of random hexamer primer and ddH2O 
in a total volume of 12 µl. After incubation at 70 ºC for 5 minutes, they are 
directly chilled on ice. After quick spin, 4µl of 5X reaction buffer, 1 µl of 
Ribonuclease inhibitor and 2µl of 10mM dNTP mix were added and incubated at 
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25 ºC for 5 minutes. Afterwards, 1 µl of M-MuLV reverse transcriptase was 
added and incubated first at 25ºC for 10 minutes, then 42 ºC for 60 minutes and 
finally 70ºC for 10 minutes. Then they were chilled on ice. 
 
2.2.9 Agarose Gel Electrophoresis of DNA fragments 
DNA fragments were separated by gel electrophoresis using agarose at concentrations of 
1.5 % w/v in 1X TBE. 0.25-0.50 µg of EtBr/ ml of the gel was used to visualize the 
DNA. DNA samples were loaded into the wells with 1X loading buffer. Electrophoresis 
was performed by running the gel for about 1 hour at 95 V. PCR products were 
visualized by UV illuminometer. The length of the DNA fragments was determined by 
comparing the fragments with molecular weight marker Gene Ruler DNA Ladder mix 
(MBI Fermentas, Catalogue # SMO333) that had been loaded and run on the same gel. 
 
2.2.10 Gel Extraction of PCR Products 
DNA purification of PCR products from agarose gel was performed using QIAEX II Gel 
Extraction Kit (Qiagen, Catalogue # 20021) according to manufacturer’s manual after 
running the PCR products on agarose gel and cutting the band from the agarose gel. 
1. The DNA bands were excised from the agarose gel with a clean, sharp scalpel by 
trying to take as little agarose as possible and transferred to a clear microfuge 
tube.  
2. The gel slices were weighed and 3 volumes of Buffer QX1 were added to 1 
volume of gel for DNA fragments 100bp-4kb.  
3. QIAEX II was resuspended by vortexing for 30 seconds and 20µl QIAEX II was 
added to the sample. 
4. To solubilize the agarose and bind the DNA, the samples were incubated at 50°C 
for 10 minutes. By vortexing every 2 minutes, QIAEX II was kept in suspension.   
5. The sample was centrifuged for 30 seconds and supernatant was carefully 
removed with a pipette tip. 
6. To wash the pellet, 500µl of Buffer QX1 was added, to remove residual agarose 
contaminants.  The pellet was resuspended by vortexing then centrifuged for 30sec 
and all traces of supernatant were removed. 
7. The pellet was washed twice with 500µl of Buffer PE (to remove residual salt 
contaminants).  The pellet was resuspended by vortexing then centrifuged for 30sec 
and all traces of supernatant were removed.  
8. The pellet was air-dried for 10-15 minutes or until the pellet becomes white.  Over-
drying should be avoided, as this may result in decreased elution efficiency. 
9. To elute DNA, 20µl of Buffer EB of Qiagen Nucleotide Removal Kit was added and 
the pellet was resuspended by vortexing then incubated at RT, 5 minutes. 
10. After incubation, the samples were centrifuged for 30 seconds then the supernatant  
containing the DNA was pipetted into a clean tube avoiding to take the Qiaex beads 
since the beads interferes with enzymatic reactions. 
11.    
2.2.11 Purification of PCR Products 
The amplified DNA fragments were purified with Nucleotide Removal Kit (Qiagen, 
Catalogue # 28304) to remove excess dNTPs, MgCl2 etc. according to manufacturer’s 
manual.  
10 volumes of buffer PN (binding buffer) to 1 volume of PCR product were added and 
mixed by pipetting. The samples were loaded into the spin column placed in the 2 ml 
collection tube. To bind DNA, the samples were centrifuged for 1 minute at 6000 rpm. 
The flow-throughs were discarded and the columns were placed back into the same 
tube. To wash the columns, 750 µl of buffer PE (wash buffer) were added and 
centrifuged for 1 minute at 6000 rpm. The flow-throughs were discarded and 
additional 250 µl of buffer PE is added then centrifuged for 1 minute at 6000 rpm. The 
flow-throughs were discarded and the columns were placed back into the same tube 
and the empty column were centrifuged for 1 minute at 13000 rpm to remove all 
residual ethanol which was present in buffer PE. The columns were placed in a clean 
1.5 ml tube and 50 µl of Buffer EB (elution buffer) were added into the center of the 
membrane in the column, let the column stand for 1 minute then centrifuged for 1 min 
at 13000 rpm.  
 17 
 
After purification, concentrations of the PCR products were determined by comparing with 
Mass Ruler DNA Ladder Mix (MBI Fermentas, Catalogue #SMO403) utilizing agarose gel 
electrophoresis. 
 
2.2.12 Automated DNA Sequencing 
PCR products were sequenced with appropriate primer pairs by ABI Prism 377 DNA 
Sequencer at Bilkent University, Department of Molecular Biology and Genetics by Tulay 
Arayici and Yeliz Yuva. For sequencing reactions, DYEnamic ET Terminator Cycle 
Sequencing Kit (Amersham Biosciences, Catalogue # US81050) was used. Cycle Sequencing 
utilizes thermostable DNA polymerase and dideoxyncleotides (ddNTPs) are used to create a 
nested set of DNA fragments with ddNTPs at the 3’ end of each fragment. Since each of the 
four ddNTPs is labeled with a different color of fluorescent dye, the reaction can be 
performed in a single tube and the sequence can be determined easily. Electropherograms of 
each sample were analyzed and the ambiguities in the sequence data were solved by 
comparing the results of the both forward and reverse primers as well as by comparing with 
sequences in the NCBI database. 
  
 
 
3. RESULTS 
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3.1. hCdc4 
To screen for alterations in hCdc4 gene, as it contains 13 exons spanning approximately 
210 kb of the genome, RT-PCR was performed, followed by direct sequencing on 15 
RNAs extracted from HCC cell lines. Two overlapping fragments covering hCdc4 were 
amplified using 1F-3R and 4F-7R primer pairs. (Figure 3.1)  
 
Figure 3.1: Positions of hCdc4 specific primers. Primers for PCR amplification: 1F-3R and 4F-7R, 
Primers for sequencing: 1F to 7R and 1R to 7R. 
 
Analysis of PCR products on agarose gel revealed the expected length of bands for 1F3R 
and 4F7R, 1047 bp and 1264 bp respectively. (Figure 3.2, Figure 3.3) No smaller and/or 
extra bands were observed, this suggest that there are no deletions or insertions that can 
be observed by conventional PCR and gel electrophoresis. Although not quantitative, it 
can be concluded that there is expression of hCdc4 in all of the cell lines tested since PCR 
was performed using equal amount cDNA synthesized from equal amount of RNA as 
template. There was no significant difference in the expression level of both products 
after 35 cycle of PCR (nested PCR was not performed) under the same PCR conditions 
between the 15 cell lines tested.  
 
Figure 3.2: RT-PCR analysis of 5’ hCdc4 cDNA using 1F and 3R primers. (1047 bp. product) 
Lanes: 1) Huh7 2) Hep3B-TR 3) Focus 4) Mahlavu 5) Hep40 6) Hep3B 7) PLC 8)SK-Hep1 
9) Snu475 10) Marker: Gene Ruler DNA Ladder mix 
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Figure 3.3: RT-PCR analysis of 3’ hCdc4 cDNA using 4F and 7R primers. (1264 bp. product) 
Lanes: 1) Marker: Gene Ruler DNA Ladder mix 2) Hep3B 3) HepG2 4) PLC 5) SK-Hep1 6) Snu475 7) 
Snu449 8)Snu423 9) Snu398 10) Snu387 
 
The PCR products were purified and sequenced using appropriate primers. 
 
Figure 3.4: The sequenced regions of hCdc4 in 15 HCC cell lines. The regions shown in blue correspond 
to clear sequence information, the regions shown in gray represents where the sequence information is not 
clear or missing. 
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No mutations ( in the F-box, WD domains and previously reported sites where mutations 
were found in other studies), abnormal transcripts, or no striking change in the 
transcription level were found among the 15 cell lines tested. 
 
3.2. B-Raf 
 
3.2.1. Exon 15 and Exon 11 Mutations 
3.2.1.1. Exon 15 mutations 
Genomic DNA from 15 HCC cell lines were analyzed by PCR followed by direct 
sequencing of PCR products. No sequence alterations were detected except T1796A 
mutation resulting in V599E change in amino acid sequence of B-Raf in SK-Hep1 cell 
line, which was previously reported. (Davies et al., 2002) 
 
Figure 3.5: Sequencing result of SK-Hep1 with BrafG-R primer showing the mutation T1796A. 
 
3.2.1.2.  Exon 11 Mutations 
12 HCC cell lines (Huh7, Focus, Mahlavu, HepG2, PLC, SK Hep1, Snu 475, Snu 449, 
Snu 423, Snu 398, Snu 387, Snu 182) were screened for mutations in exon 11. DNA 
extracted from 12 HCC cell lines were amplified by PCR (Figure 3.6), purified and 
sequenced with appropriate primers. No alteration was found in the cell lines in exon 11.  
 
Figure 3.6: B-Raf exon 11 PCR products of HCC cell lines. Lanes: 1) Marker (Gene Ruler DNA Ladder 
Mix) 2) SK-Hep1 3) Focus 4) SNU182 5) Huh7 6) Mahlavu 7) HepG2 8) PLC 9) SNU449 10) SNU423 11) 
SNU398 12) SNU387 13) SNU475 14) Marker (Gene Ruler DNA Ladder Mix) 
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3.2.2. ARMS 
3.2.2.1 ARMS test for HCC cell lines 
15 HCC cell lines and 58 HCC tumours were screened for exon 15 mutations using 
ARMS test. (Figure 3.7, 3.8) DNA extracted from cell lines and tumours have been 
subjected to ARMS test and the positive ones were confirmed via sequencing. V599E 
mutation in SK-Hep1 cell line (Figure 3.5) was used as (+) control in the experiments.   
 
 
Figure 3.7: ARMS results of exon15 T1796A mutation for HCC cell lines (a). Lanes: 1) Marker (Gene 
Ruler DNA Ladder Mix), 2-3) SK-Hep1, 4-5) Huh7, 6-7) Focus, 8-9) Hep40, 10-11) HepG2,  
12-13) PLC, 14-15) SNU398, 16-17) SNU182 18) Marker (Gene Ruler DNA Ladder Mix)  
N: for the normal allele M: for the mutated allele 
 
Figure 3.8: ARMS results of exon15 T1796A mutation for HCC cell lines (b). Lanes: 1) Marker (Gene 
Ruler DNA Ladder Mix), 2-3) SK-Hep1 (+ control) 4-5) SNU387 6-7) Hep3B 8-9) Mahlavu 10-11) 
SNU475 12-13) SNU423 14-15) SNU449 16-17) SNU182 (- control) 18) Marker (Gene Ruler DNA Ladder 
Mix)  
N: for the normal allele M: for the mutated allele 
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3.2.2.2. ARMS test for HCC tumours 
 
Figure 3.9: ARMS results of exon 15 T1796A mutation for HCC tumours (a). Lanes: 1) Marker (Gene 
Ruler DNA Ladder Mix), 2-3) SK-Hep1 (+ control) 4-5) C14  6-7) T70 8-9) T75 10-11)T78 12) Marker 
(Gene Ruler DNA Ladder Mix)  N: for the normal allele M: for the mutated allele 
Figure 3.10: ARMS results of exon 15 T1796A mutation for HCC tumours (b). Lanes: 1) Marker (Gene 
Ruler DNA Ladder Mix), 2-3) T39 4-5) N38 (corresponding normal tissue for T39) 6-7) T83 8-9) SNU182 
(- control) 10) Marker (Gene Ruler DNA Ladder Mix) N: for the normal allele M: for the mutated allele. 
 
Within 58 tumours tested for V599E mutation, 1 tumour (T39) was found to have the 
mutation. (Figure 3.10) 
In order to confirm the mutation detected in ARMS result, sequencing for sample T39 is 
performed. Although the mutation couldn’t be seen in the sequencing results, it is obvious 
in more sensitive ARMS test indicating that proportion of normal cells was high in the 
sample. (Figure 3.11) 
 
Figure 3.11: Sequencing result with BrafG-R primer for HCC tumour T39. Although mutation cannot 
be observed in sequencing results it is observable in the more sensitive ARMS test showing that the 
proportion of the normal cells was high in the sample. 
 
  
 
 
4. DISCUSSION 
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4.1. hCdc4 
Several studies have shown that chromosomal deletions at the 4q are associated with 
human HCCs (76.5% by Shipley et al. and 72.7% by Piao et al.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: hCdc4/Fbwx7 gene locus on chromosome 4q 
 Marker  cM 
 AFMB297XA5  141.40 
 AFMA286XH5  142.00 
 AFM225XB10  143.80 
 AFM031XA7  146.40 
 AFMB336ZA9  146.40 
 AFM318XG9  146.40 
 AFM242YE9  146.40 
 AFM294VH5  152.50 
 AFM045XC1  153.50 
 AFM200ZH12  153.60 
 AFM308ZG5  154.40 
 AFMA246XD9  155.50 
 AFMB362XC1  155.70 
 AFM196XE1  157.90 
 AFM225ZB2  158.50 
 AFM290VC5  158.50 
 AFMA040ZB9  158.50 
 AFMB337YC1  159.10 
 AFMA054TD5  160.90 
 AFM036XG11  161.50 
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However no TSG involved in liver carcinogenesis has been identified on this 
chromosome.  
 
On the other hand, there is strong evidence that cyclin E is involved in carcinogenesis. 
Genetic analyses have revealed that one of the commonly altered genes in HCC is the 
cell cycle regulator cyclin E (Malumbres et al., 2001). Overexpression of cyclin E was 
found in 70% of HCC patients, which correlated with the poor prognosis of those 
patients (Jung et al., 2001). In addition, Pascale et al. and Masaki et al. showed that 
overexpresssion of cyclin E occurred in HCC of chemically induced HCC of Fischer 
344 rats and in preneoplastic and neoplastic liver of Long Evans Cinnamon rats (Pascale 
et al., 2002: Masaki et al., 2000). In fact, overexpression of cyclin E and skp2 (which 
promotes p27 degradation and thereby activates cyclinE/cdk2) synergistically promote 
cell cycle progression in cultured hepatocytes in the absence of mitogen or in the 
presence of growth inhibitors and in vivo; hepatocyte replication and hyperplasia of the 
liver (Nelsen at al., 2001). These previous data suggest the possibility that cyclin E 
might play a role in the carcinogenesis or progression of human HCC. 
 
Recently, two research teams have identified a gene mutation that leads to persistently 
elevated levels of Cyclin E protein and cell proliferation in human tumor cells (Moberg 
et al, 2001; Strohmaier et al., 2001). Having a role in the regulation of cyclin E 
expression hCdc4 is proposed to be a TSG and its mutations have been shown in 
ovarian carcinoma, ALL (acute lymphoblastic leukemia and breast carcinoma cell lines 
and endometrial tumours. (Moberg et al., 2001; Strohmaier et al. 2001; Spruck et al. 
2002). hCdc4 gene mutations were accompanied by loss of heterozygosity and 
correlated with aggressive disease. The observation of LOH involving 4q in those 
tumors suggests that hCdc4 gene acts as a tumor suppressor, in keeping with the "two-
hit" model. Additional evidence suggests that this newly identified gene, hCdc4, may 
also be involved in another cancer related pathway, the Notch signaling pathway 
(Gupta-Rossi et al., 2001). 
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Interestingly, hCdc4 is located on chromosome 4q where the most frequent LOH 
observed in HCCs.  
 
Based on these facts; we consider hCdc4 is a good candidate tumour suppressor gene 
that might be involved in HCC. 
 
The hCdc4 gene is composed of 13 exons spanning approximately 210 kb of the 
genome. hCdc4 is an F-box protein that involves an F-box and seven WD repeats which 
is shown to be involved in protein-protein interactions important in substrate recognition 
for ubiquitination (Bai et al., 1996; Skowyra et al. 1997) of cyclin E, thus targeting it for 
destruction. F-boxes and WD40 repeats are typically found in proteins that function as 
the substrate-recognition components of SCF-type ubiquitin ligase (E3) complexes.  
 
 
 
 
 
    1                    2         3  4                                   5  6  7  8          9                                                        10 
1) OV 1063 E? ter 
2) MDAH2774 codon261ter 
3) (endometrial tumour) Lys? Ser, ter codon 376  
4) (endometrial tumour) Arg?ter 
5) CCRF-CEM R?C 
6) (endometrial tumour) Arg?His 
7) (endometrial tumour) Arg?Lys, ter codon 476 
8) (endometrial tumour) Arg?Gln  
9) SK-OV3 R?L 
10) (endometrial tumour) Arg?ter 
 
 
Figure 4.2: hCdc4 mutations reported previously in cell lines by Moberg et al. (Moberg et al., 2001) and 
in endometrial tumours reported previously by Spruck et al. (Spruck et al., 2002)  
 
Observed cancer related mutations were localized on functionally important domains of 
the protein such as F-box or WD domains (Figure 4.2). 
 
 
N-t F-BOX  WD1 WD2 WD3 WD4 WD5 WD6 WD7 C-t 
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Knudson has proposed that a TSG is inactivated by LOH in one allele and by mutation 
in the other (Knudson, 1996). Since this hypothesis has developed, homozygous 
deletions, silencing by methylation were reported for several Tumour Suppressor Genes 
such as p16, PTEN and SOCS1. (Nagai et al., 2003; Schagdarsurengin et al., 2003; 
Zhang et al., 2002; Yu et al., 2002)   
 
In this study we performed sequence and expression analysis of hCdc4 gene in 15 HCC 
cell lines. The transcript levels of hCdc4 were almost the same in all cell lines tested. 
This suggests that there is no silencing or over expression of hCdc4 in HCC cell lines. 
Although our RT-PCR method is not quantitative, we would expect to detect drastic 
change in expression level. We observed expected length of RT-PCR products for all 
cell lines, which indicate that there was no detectable deletion or insertion of hCdc4 
gene in these cell lines.  Additionally, our mutation analysis on the hCdc4 using RT-
PCR followed by direct sequencing did not reveal any alteration in 15 HCC cell lines. In 
order to cover all coding region, we sequenced ORF of hCdc4 using primers whose 
products expected to overlap each other, however we missed some sequencing 
information for most of the cell lines (see Figure 3.4). But sequencing reads were clear 
where the most of the mutations described previously (F-box and WD domains). Thus 
we concluded that there is no mutation on functionally important domains of the protein 
hCdc4 in HCC cell lines.  
 
Though frequent LOH reported within this region provides the first requirement, in our 
study no mutation and/or deletion, which may provide the second requirement, or no 
drastic change in expression level (although our method is not quantitative), which may 
otherwise indicate silencing by another mechanism, was observed. 
 
The genes that are frequently involved in HCC such as p53, β-catenin and axin are also 
reported to be frequently mutated in HCC cell lines. (Sayan et al., 2001; Olivier et al., 
2002; Satoh et al., 2000; Cagatay and Ozturk, 2002) Since inactivation of hCdc4 due to 
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homozygous deletions, mutations or methylation was not observed in any HCC cell 
lines tested, we have not extend this study to the HCC samples. 
Altogether these findings suggest that alteration of this gene is not a frequent event in 
hepatocarcinogenesis. Other genes that may have role in accumulation of cyclin E in 
HCC should be searched. 
4.2. B-RAF 
B-Raf gene is located on chromosome 7q34 and encodes a 765 aa. proto-oncogenic 
serine-threonine protein involved in transduction of mitogenic signals from the cell 
membrane to the nucleus via MAP kinase pathway. It belongs to Ser/Thr family of 
protein kinases. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 4.3: Exons and motifs of B-Raf. Amino acids highlighted in black are identical and those highlighted in 
gray are similar among A-Raf, Raf-1 and B-Raf. The three conserved regions CR1–3 are highlighted by the black 
arrows. The GXGXXG motif and the activation segment are indicated by the hatched bars. 
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Figure 4.4: B-Raf protein. CR1, CR2, CR3: conserved domains among Raf-1, A-Raf and B-Raf. CR1 
contains two domains that bind to Ras-GTP: Ras binding domain (RBD), Cystein rich domain (CRD), and 
a putative zinc finger domain. CR2 contains regulatory phosphorylation sites (serine threonine rich 
residues). CR3 contains the kinase domain (with possible phosphorylation sites indicated). 
 
B-Raf mutations are found in a wide range of cancers. Missense mutations of the B-
RAF gene in approximately 70% of human malignant melanomas and 15% of colorectal 
cancers were reported (Davies et al., 2002). High prevalence of B-RAF mutations is 
described in papillary thyroid cancers (Kimura et al., 2003).  Mutations were also 
detected at a low frequency in gliomas, lung cancers, sarcomas, ovarian carcinomas and 
breast cancers.  
 
It seems that B-RAF activating mutations play an important role in different organ 
carcinogenesis. Eventhough mutational activation of Ras is not a frequent event in 
human hepatocarcinogenesis, Ras mutations in few HCC cases were reported. Some 
animal models treated with carcinogen display also frequent Ras mutations (Boivin-
Angele et al., 2000; Barbin A., 2000; Froment et al., 1994) suggesting that RAS-MAP 
kinase signaling pathway may be important in hepatocarcinogenesis. Recent work by 
Davies et al. has identified B-Raf mutations in several cancers but no primary HCC 
samples and only seven HCC cell lines were screened. We therefore decided to 
determine the incidence of B-Raf mutations in our HCC cell lines and patient 
population.  
 
Genomic DNA from 15 HCC cell lines is screened for sequence variants using PCR and 
direct sequencing analysis. Mutation analysis was restricted to exon 11 and 15 of B-
RAF gene as all previously reported mutations cluster to these two exons within the G 
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loop in the ATP binding domain of the kinase domain and the activation segment 
respectively. 
 
We observed only one V599E mutation in SK-Hep1 cell line that has been reported 
previously. Since we found V599E mutation in one cell line, we extended our study to 
additional 58 HCC patient samples restricted to this particular mutation. We used 
ARMS (allele-specific amplification method) to evaluate the incidence of B-RAF 
activating mutations in patients with HCC. We found one additional mutation in one 
HCC sample (T39). In order to confirm the mutation detected in T39 sample we 
amplified exon 15 with the primers covering this exon and sequenced PCR product 
directly. We were not able to detect this mutation by direct sequencing.  Our result is 
concordant with those reported previously by Pollock et al. (2002), and explained by 
higher sensitivity of ARMS method compared to the sequencing. Altogether, we found 
two tumors displaying BRAF mutations out of 72 samples tested (3%).  
 
Eighty-nine percent of the B-RAF mutations encode amino acid changes within the 
activation segment, with the V599E (T?A change at nucleotide 1796) mutation 
accounting for 92% of these mutations. Other mutations detected within the activation 
loop at a lower frequency are V599D, L596V, L596R, G595R and F594L. Eleven 
percent of the mutations are found in the glycine residues of the G loop GXGXXG motif 
in the ATP-binding domain of the kinase domain affecting G463, G465 and G468. Thus 
using direct sequencing method on cell lines we would find if one of these mutations 
were present.   
 
In a very recent report by Tannapfel et al, (2003) neither BRAF nor KRAS mutations 
were detected in 25 HCC samples. However in our study we found BRAF V599E 
mutation in 1/58 HCC tumours and 1/15 HCC cell lines giving an overall percentage of 
3 %. The difference in the results might be due to etiological factors meaning that 
differences in the origins of the tumour samples which in our case was African origin. A 
minor factor might be the cause of the mutation we found and that factor may not be 
involved in the region from where the tumour samples were taken by the other group. 
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Our results suggest that B-Raf may be occasionally involved in hepatocarcinogenesis. 
This is also the case for Ras which is also rarely mutated in human HCCs. Our results 
together with previously published HCC mutation studies and reports on HCC animal 
models suggest that MAP kinase pathway might be involved in hepatocarcinogenesis 
but neither B-Raf nor Ras are the major player of this pathway in this event. Thus, other 
members of this pathway should be evaluated for mutations in HCC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
5. FUTURE 
PERSPECTIVES 
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Given the importance of cyclin E over expression in HCC as well as other cancers, it 
would not be surprising to see alteration of the cyclin E degradation pathway in these 
cancers. Our next step will be to find out if the other components of this pathway such 
as Skp1 and Cul 1 are altered in cancers. It is likely that multiple cyclin E degradation 
pathways operate in mammals since the Roberts et al. has recently found that another 
mammalian cullin, Cul3, also influences cyclin E levels in mice and in cell lines (Singer 
et al., 1999). It would be also interesting to test this gene and identify unknown 
members of cyclin E degradation pathway.  
 
There is no doubt that Ras/Raf/MEK/ERK signaling pathway is involved in 
carcinogenesis. However neither B-Raf nor Ras are the major players of this pathway in 
this event. Thus, other members of this pathway such as RHEB and Rho-GAP will be 
evaluated for mutations in HCC in the further study. 
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